Swissmedic receives second marketing authorisation application for a coronavirus vaccine

28. Oktober 2020 – At the end of last week, the pharmaceutical company Pfizer filed a marketing authorisation application for a vaccine against the SARS-CoV-2 virus based on the mRNA technology developed by BioNTech. The mRNA components contain the blueprint of the new corona virus, thus feigning infection with the SARS-CoV2 virus to the human organism.

For further information, see here.